Turkey aims to significantly increase domestic pharma production

17 August 2015

The government of Turkey plans to create conditions for a significant increase of the domestic production of pharmaceutical products, as part of the ongoing reform of the national health care sector.

According to recent statements by Eyup Gumush, Turkish Deputy Minister of Health Care, a particular attention will be paid to increasing the production of vaccines, the majority of which are currently imported.

Mr Gumush added that, as part of the plans, the Turkish government aims to establish domestic production of at least half of the drugs from the list of vital during the next five-seven years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical